Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed malignant melanoma
Stage III (unresectable) or Stage IV disease which may have been treated with up to one prior cytotoxic chemotherapy and/or up to 3 other therapeutic regimens
Willing to undergo up to 3 biopsies of an accessible lesion
You may not be if
Active/symptomatic brain metastases
Primary ocular melanoma or primary tumor of unknown origin
Concurrent autoimmune disease
Previous treatment with a CD137 agonist or CTLA-4 inhibitor
Clareo Health | Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
